论文部分内容阅读
目的探讨沙美特罗替卡松粉吸入剂联合孟鲁司特钠治疗儿童咳嗽变异性哮喘的疗效。方法选取2010年11月至2013年11月我院所收治的84例咳嗽变异性哮喘患儿,将其分为3组,沙美特罗替卡松粉吸入剂组患儿每日吸入2次沙美特罗替卡松粉吸入剂;孟鲁司特钠组患儿每日吸入1次孟鲁司特钠;联合治疗组患儿每日吸入2次沙美特罗替卡松粉吸入剂,同时每日吸入1次孟鲁司特钠,疗程均为8周。结果联合治疗组治疗后症状积分明显低于孟鲁司特钠组、沙美特罗替卡松粉吸入剂组,差异有统计学意义(P<0.05)。孟鲁司特钠组复发7例(25.0%),沙美特罗替卡松粉吸入剂组复发6例(21.4%),联合治疗组复发3例(10.7%),可见联合治疗组复发率最低,差异有统计学意义(P<0.05)。结论对于儿童咳嗽变异性哮喘治疗而言,应用沙美特罗替卡松粉吸入剂联合孟鲁司特钠临床疗效较佳,无不良反应及并发症。
Objective To investigate the effect of salmeterol and fluticasone powder inhalation combined with montelukast on children with cough variant asthma. Methods Eighty-four children with cough variant asthma admitted from November 2010 to November 2013 in our hospital were divided into three groups. The children with inhaled salmeterol-ticainine powder inhaled twice a day Montelukast sodium inhalation once a day in patients with montelukast sodium; combined treatment group received inhaled daily inhaled salmeterramycin twice a day, while each On the 1st inhalation of montelukast sodium, treatment were 8 weeks. Results The symptom score of combined treatment group was significantly lower than that of montelukast sodium group and salmeterol truss powder inhaler group, the difference was statistically significant (P <0.05). Recurrence occurred in 7 patients (25.0%) in the montelukast sodium group, 6 patients (21.4%) in the salmeterol cortese powder inhaler group, and 3 patients (10.7%) in the combination therapy group. The relapse rate was the lowest in the combination therapy group , The difference was statistically significant (P <0.05). Conclusion For children with cough variant asthma treatment, the application of salmeterol and fluticasone powder inhalation combined with montelukast sodium clinical efficacy is better, no adverse reactions and complications.